Payment overview · 2025
General Payments
$377.40
23 reported records · 10 companies
Healthcare provider profile · identity verified
Brent Richard Yoder, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · FLOMATON, AL · NPI 1497831184
Verified facts
What the public records show
CMS Open Payments records show Brent Richard Yoder, CRNP received $377.40 in general payments during 2025 across 23 reported records.
SHIELD THERAPEUTICS INC accounted for 17.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $65.25 | 17.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $63.57 | 16.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.95 | 16.1% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $46.61 | 12.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.47 | 11.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.62 | 7.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.37 | 5.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.83 | 4.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.50 | 4.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.23 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $377.40 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $65.25 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $60.95 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $48.87 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $48.87 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $46.61 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $41.47 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $41.47 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.86 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $29.62 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.37 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 46 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 41 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 274 | 168 |
| Amlodipine Besylate | Amlodipine Besylate | 260 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 259 | 86 |
| Lisinopril | Lisinopril | 207 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 177 | 56 |
| Amoxicillin | Amoxicillin | 166 | 112 |
| Metformin Hcl | Metformin Hcl | 163 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 149 | 48 |
| Gabapentin | Gabapentin | 148 | 36 |
| Meloxicam | Meloxicam | 145 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 47 |
| Omeprazole | Omeprazole | 124 | 43 |
| Atorvastatin Calcium | Atorvastatin Calcium | 114 | 45 |
| Montelukast Sodium | Montelukast Sodium | 107 | 39 |
| Trazodone Hcl | Trazodone Hcl | 96 | 20 |
| Furosemide | Furosemide | 90 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 30 |
| Losartan Potassium | Losartan Potassium | 85 | 34 |
| Simvastatin | Simvastatin | 84 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 26 |
| Tramadol Hcl | Tramadol Hcl | 79 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 34 |
| Potassium Chloride | Potassium Chloride | 78 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 29 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 74 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 17 |
| Carvedilol | Carvedilol | 68 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 26 |
| Ondansetron Odt | Ondansetron | 68 | 32 |
| Azithromycin | Azithromycin | 66 | 54 |
| Levofloxacin | Levofloxacin | 64 | 49 |
| Alprazolam | Alprazolam | 62 | 22 |
| Celecoxib | Celecoxib | 57 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 55 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 53 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 15 |
| Fluconazole | Fluconazole | 49 | 33 |
| Temazepam | Temazepam | 48 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 16 |
| Allopurinol | Allopurinol | 46 | 16 |
| Eliquis | Apixaban | 46 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 27 |
| Ozempic | Semaglutide | 45 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 13 |
| Famotidine | Famotidine | 41 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 15 |
| Mounjaro | Tirzepatide | 41 | 11 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 32 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 40 | 13 |
| Glipizide | Glipizide | 38 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Sucralfate | Sucralfate | 35 | 17 |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Estradiol | Estradiol | 33 | 11 |
| Glimepiride | Glimepiride | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Glipizide Er | Glipizide | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | 22 |
| Linzess | Linaclotide | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 29 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Glyburide | Glyburide | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Mirtazapine | Mirtazapine | 23 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 15 |
| Valsartan | Valsartan | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 17 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Ofloxacin | Ofloxacin | 16 | 15 |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 11 |
| Methocarbamol | Methocarbamol | 15 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $377.40 · 23 records | SHIELD THERAPEUTICS INC | ACCRUFER, CAPLYTA, ELIQUIS, FARXIGA, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error